Drug Approval | August 28, 2022
Cipla receives 6 observations from USFDA for Goa facility
There are no data integrity (DI) observations.
There are no data integrity (DI) observations.
With the receipt of the EIR, the inspection stands successfully closed.
The company has received 1 (ONE) observation on Form 483 with respect to ANDA filed for the product to be manufactured at the said Facility.
This biopharmaceutical facility is one most significant private sector investment ever in the Middletown region
The OAI classification implies that the US FDA may withhold approval of any pending product applications or supplements filed from this facility till the outstanding observations are resolved
With this expansion, the Grand Island site provides redundant capacity to support global supply of media and further extends the site’s capabilities to produce the high-quality technology and materials needed for the development and commercial manufacturing of vaccines and biologic therapies
he US FDA has issued six observations pursuant to the completion of the audit.
The GMP facility is equipped with state of art machinery for the needs of Global commercial requirements
The company has been issued a Form 483 with two observations which the company will address within the stipulated timeline.
This GMP and Pre-Approval Inspection is part of the routine business operations and the company shall submit to US FDA within the stipulated timeline
Subscribe To Our Newsletter & Stay Updated
